Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MGLL | Q99685 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | PARL | Q9H300 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL108457 | 1.00 | TSHR (0.39) | TSHRMGLLNFKB1CYP2C19ALDH1A1 | |
| SCHEMBL20404645 | 0.92 | MGLL (0.36) | MGLLPARL | |
| SCHEMBL111364 | 0.92 | MGLL (0.36) | MGLLPARL | |
| SCHEMBL37884 | 0.92 | MGLL (0.36) | MGLLPARL | |
| SCHEMBL23584357 | 0.81 | MGLL (0.32) | MGLL | |
| SCHEMBL13286374 | 0.81 | MGLL (0.32) | MGLL | |
| SCHEMBL13286350 | 0.81 | MGLL (0.32) | MGLL | |
| SCHEMBL4003476 | 0.81 | MGLL (0.33) | MGLL | |
| SCHEMBL4003479 | 0.81 | MGLL (0.33) | MGLL | |
| SCHEMBL2573222 | 0.79 | MGLL (0.36) | MGLLPARL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3351248-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | Ardelyx, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| US-20120208291-A1 | METHODS AND COMPOSITIONS FOR MEASURING HIGH AFFINITY INTERACTIONS WITH KINETIC IMAGING OF SINGLE MOLECULE INTERACTION (KISMI) | UNIVERISTY OF UTAH RESEARCH FOUNDATION (US) | 2012-08-16 | — | — | US | disclosed |
| EP-2424971-A1 | METHODS AND COMPOSITIONS FOR MEASURING HIGH AFFINITY INTERACTIONS WITH KINETIC IMAGING OF SINGLE MOLECULE INTERACTION (KISMI) | University of Utah Research Foundation (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010127247-A1 | METHODS AND COMPOSITIONS FOR MEASURING HIGH AFFINITY INTERACTIONS WITH KINETIC IMAGING OF SINGLE MOLECULE INTERACTION (KISMI) | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208291-A1 | METHODS AND COMPOSITIONS FOR MEASURING HIGH AFFINITY INTERACTIONS WITH KINETIC IMAGING OF SINGLE MOLECULE INTERACTION (KISMI) | MPI, MKI67, GDI2 | TSHR 4547/4885MGLL 1656/4885NFKB1 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.